key: cord-0894801-i00urbty
authors: Duarte, Geraldo; Coutinho, Conrado Milani; Rolnik, Daniel Lorber; Quintana, Silvana Maria; e Silva, Ana Cláudia Rabelo; Poon, Liona C.; da Silva Costa, Fabrício
title: Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low- and middle-income countries
date: 2021-09-03
journal: AJOG Glob Rep
DOI: 10.1016/j.xagr.2021.100020
sha: 4194fcc1fce1c8822e54277cae498662429fe4ee
doc_id: 894801
cord_uid: i00urbty

Women in the pregnancy-puerperal cycle or those who are lactating have been deliberately excluded from participating in COVID-19 vaccine clinical trials that aimed to evaluate either the efficacy in inducing the formation of neutralizing antibodies or the investigational products’ safety profile. Exclusion of pregnant and lactating women from such studies still certainly inequitably deny these women access to COVID-19 vaccines since these products’ availability became increasingly available to non-pregnant people and even during pregnancy in high-income settings. In this clinical opinion article, we discuss aspects of the prolonged pandemic, the emergence of viral variants, the risks of severe complications of COVID-19 in pregnant women, and the disproportionate impact on low- and middle-income countries. We argue that the decision to receive the COVID-19 vaccine should be a joint decision between the pregnant or lactating women and the healthcare providers while considering the available data on vaccine efficacy, safety, the risks of SARS-CoV-2 infection in pregnant women, and the woman's individual risk for infection and serious illness. The various types of vaccines already in use and their safety and effectiveness, and the potential risks and benefits of their administration to pregnant or lactating women are reviewed.

Due to the lack of specific treatment against coronavirus disease 2019 (COVID- 19) and low adherence to protective measures to prevent the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the pandemic continues to cause a large number of deaths worldwide. The SARS-CoV-2 is also mutating over time. 1 Due to the failure of infection control measures to stop the spread of the virus, 2 vaccines have emerged as the best hope to control the pandemic, which has been supported by available evidence so far. [3] [4] [5] [6] [7] [8] [9] [10] [11] Certain vulnerable groups have been identified as having greater risk for developing severe COVID-19 and should be considered as priorities for vaccine administration. These include healthcare providers who work at the frontline, elderly people, and patients with heart and respiratory comorbidities, diabetes mellitus, obesity, neurological diseases and those who are immunosuppressed. 12 Physiological adaptations to the immune and cardiopulmonary systems imposed by the pregnancy, per se, predispose pregnant and postpartum women to an increased risk of developing serious complications from COVID- 19 . 13 In this opinion article, we discuss the implications of excluding pregnant and lactating women from vaccine trials from a public health perspective, emphasizing its undesirable effects on low-and middle-income countries (LMIC) that are severely impacted by the pandemic.

On the basis of non-maleficence, women in the pregnancy-puerperal cycle or those who are lactating have been deliberately excluded from participating in COVID- 19 vaccine clinical trials that aimed to evaluate either the efficacy in inducing the formation of neutralizing antibodies or the investigational products' safety profile. 14, 15 Exclusion of pregnant and lactating women from RCTs still certainly inequitably deny these women access to COVID-19 vaccines since these products' availability became increasingly available to non-pregnant people and even during pregnancy in high-income settings.

Although few animal and human studies assessed pregnant individuals, [16] [17] [18] [19] [20] there is still lack of robust evidence about safety and effectiveness for the majority of available vaccines in the pregnant population. 17 Secondary these limitations, professional guidelines regarding vaccine administration to pregnant and lactating women are ambiguous, considering maternal and perinatal risks of the disease and theoretical risk of the vaccine. 21 Moreover, the lack of a clear policy to promote vaccination for these women may play an additional role to their limited access to these products in LMIC, where vaccine availability has been a major issue.

To determine whether vaccines should be administered to pregnant and lactating women, studies specifically targeting these groups are needed. Herein, we describe the prolonged pandemic, the emergence of viral variants, the higher risk of severe complications of COVID-19 in pregnant women, the disproportionate impact on LMIC, the risk of vertical transmission of SARS-CoV-2, and the perinatal prognosis of pregnancies complicated by COVID-19. Lastly, we briefly review the various types of vaccines already in use and their safety and effectiveness in the non-pregnant population. Given the recent approval and continued development of many different vaccines, studies of this subject are warranted.

Although the herd immunity effect, defined as the reduction in the spread of a disease secondary to large community immune protection by infection, was expected in some communities with high rates of SARS-CoV-2 infection early in the pandemic, it has not been consistently demonstrated yet. For example, during the first wave of the pandemic, in Manaus, Brazil (capital of the state of Amazonas), 75% of the population had serologically confirmed infection, whereas in São Paulo, Brazil (capital of the state of São Paulo), this rate was 25%. 22 However, during the Brazilian second wave of the pandemic, which is currently ongoing, infection rates in Manaus are at least twice as high as in the first wave of the pandemic. 23 Therefore, even in locations where infection rates were initially high, current infection rates remain high, meaning that no clear evidence of effective herd immunity has been achieved.

In patients who have had SARS-CoV-2 infection, the duration of neutralizing antibodies production is variable and, in some cases, does not last for more than 90 days, mainly in asymptomatic individuals or in those with a mild form of the disease. 24 This may become another factor contributing to the pandemic not being under control after more than one year.

As an RNA virus, mutations can accumulate over time during the pandemic. 25, 26 Some of these mutations alter the pathophysiological characteristics of the virus, as demonstrated for mutations identified in various parts of the world, such as the United Kingdom, South Africa and Brazil. [27] [28] [29] For some of the most widely studied mutations to date, the infection rate of the mutant virus is higher than that of the originally identified virus at the beginning of the pandemic. New mutant viruses have been shown to amplify the interface area of the receptor-binding domain (RBD) of the angiotensin-converting enzyme

Cardiopulmonary and immune adaptations that occur during pregnancy alter the immune defenses against some forms of viral infection, predisposing women to developing serious complications, particularly in the case of respiratory viruses. 2, 31, 32 Existing literature addressing the influence of SARS-CoV-2 infection on maternal outcomes was initially inconsistent. However, currently there seems to be a consensus that severe cases of COVID-19 are more common among pregnant women at higher age strata and with comorbidities such as obesity, heart disease, asthma and diabetes mellitus. [33] [34] [35] Additionally, a higher rate of cesarean delivery is commonly reported for women with COVID-19 (odds ratio (OR): 3.0; 95% confidence interval (CI) 2.0-5.0), often indicated for severe complications related to this infection. 36 While some studies have not reported a worse prognosis among pregnant women when compared to non-pregnant women, 37,38 others have found the opposite results when considering the need for hospital admission, 39 admission to intensive care unit (ICU), 33, [39] [40] [41] [42] [43] and evolving respiratory failure requiring invasive ventilation and extracorporeal membrane oxygenation (ECMO). 33 45 In an United States cohort, COVID-19 case-fatality rate in pregnant people was 13.6 times higher than in age matched non-pregnant individuals with COVID- 19. 39 There are also many differences in COVID-19 pregnancy outcomes when considering the degree of economic development in certain countries, some of which are better equipped and have more resources. 46 Brazil has the largest number of cases of maternal death resulting from infection by SARS-CoV-2. 47 Among all causes of severe acute respiratory syndrome (SARS), SARS-CoV-2 infection is the most frequent in pregnant women during the third trimester and in the postpartum period, and encompasses a worse disease prognosis in patients with concomitant diabetes mellitus, hypertension and obesity. 35 Information regarding pregnant women with COVID-19 shows wide variation in the rates of perinatal complications compared to that in pregnant women without COVID-19, likely because of different sample sizes, differences in inclusion criteria and outcome definitions, and possibly due to the different impact of the pandemic on different countries' health systems. 48 Even considering these limitations, it appears that approximately 25% of pregnancies result in preterm births (OR: 3.0; 95% CI 1.1-7.8), with an increased rate of neonatal ICU admission (odds ratio: 3.1; 95% CI 2.0-4.7). Recent national reports, 49, 50 multinational cohorts 51 and systematic reviews 52 emphasized the increased incidence of preeclampsia, preterm birth and stillbirth in pregnant women with SARS-Cov-2 infection, mainly for those with symptomatic and severe cases. 49, 51 Preterm birth is the most important perinatal complication according to the majority of publications given its associated short and long-term complications in the neonates. 33, [49] [50] [51] According to the INTERCOVID cohort, diagnosis of COVID-19 among pregnant women increased severe neonatal morbidity index (RR: 2.7. 95% CI 1.7-4.2) and severe perinatal morbidity and mortality index (RR: 2.1. 95% CI 1.7-2.8). 51 Association with increased rates of low birth weight rates varied according to data in the literature from a OR of 9.0 (95% CI 2.4-30.0) 36 to no difference from populational reports. 50 The World Association of Perinatal Medicine (WAPM) study of consecutive pregnant women with laboratory-confirmed COVID-19 from (95% CI 1.0%-4.8%); 2.0% neonatal deaths (95% CI 0.9%-4.6%), and 4.2% perinatal mortality (95% CI 2.3%-7.2%). 53, 54 Chronic histiocytic intervillositis and syncytiotrophoblast necrosis were initially described in the placentas of patients with documented SARS-CoV-2 infection and could potentially be related to adverse pregnancy outcomes and transplacental fetal infection, but differences regarding placental pathology correlated with several underlying clinical obstetric and fetal conditions were not observed between infected and non-infected women in recent publications. 55, 56 Studies have indicated that rates of possible vertical transmission of SARS-CoV-2 are low. 21, 57 Although the pooled rate of possible vertical transmission based on case series, case-control and cohort studies was estimated to be 3.2%, 58 this figure falls to 0.9% when only cohort studies are taken into consideration. 59 Potential reasons for the differences observed in these rates are different sample sizes, time at which neonatal infection evaluations were carried out, and different criteria for the definition of the vertical transmission among studies. 36 Although there are limited data on first and early second trimester maternal infection, no causality between SARS-CoV-2 and fetal malformations or clinical manifestations has been observed in infants, even in the rare cases when congenital infection is confirmed. 58 The absence of a typical neonatal clinically recognizable pattern emphasizes the importance of an almost exclusively-oriented laboratory diagnosis. 60 samples. 57 Recognizing the limited evidence available, the World Health Organization has proposed the latest guidance for definition and categorization of the timing of mother-tochild transmission of SARS-CoV-2 in an attempt to achieve standardized international consensus definitions. 64 Although it is an uncommon event, the possibility of vertical transmission of SARS-CoV-2 makes it difficult to predict the future effects on the health of infected neonates.

Additionally, the pathophysiological mechanisms that increase the rates of prematurity, low birth weight, placental damage and perinatal death are unknown. Because of these uncertainties for both the pregnant women and their children, the best option is prevention.

Vaccines against COVID-19 approved for use in humans or in phase 3 trials that are available for clinical use can be classified for didactic purposes in three different groups based on the applied technology. The first group employs well established strategies, such as the use of inactivated viruses. 6 The second group includes technologically advanced vaccines, mainly based on the induction of spike (S) protein synthesis using SARS-CoV-2 messenger RNA (mRNA) fragments. Lipid nanoparticles are used to carry these gene instructions to the ribosomes without entering the cell nucleus. 65 Protein S is responsible for the interaction of the virus with the ACE2 receptor of the host cell and, when this antigen is exposed to the immune system, it triggers the immune response with the production of antibodies. 66 The third group of vaccines uses viral vectors to carry gene information to the cell nucleus, which also express and control the production of protein S. Adenoviruses are the most widely used vectors. Their genetic material is removed so that they cannot replicate but are incorporated into double-stranded DNA sequences containing the protein coding information in the nucleus. 67 The only antiviral vaccines that should not be used in pregnant women are those using the attenuated live form of the disease vector, such as the vaccines against measles and rubella viruses. The use of this type of vaccines in pregnant women is only authorized in very special situations, when the benefits clearly surpass the risks, such as when considering the use of yellow fever vaccine for patients who cannot avoid travelling to endemic areas. 68 Vaccines that are developed based on viral antigens that are inactivated by chemical or physical agents induce a less intense immune response than attenuated virus vaccines and can be used during pregnancy. Vaccines that are most frequently used in pregnant women and that are based on inactivated virus are the vaccines for influenza (seasonal flu) and hepatitis A; these vaccines were approved for use during pregnancy several years ago. Vaccine against influenza is particularly important and has been expressly recommended for use in all women in the pregnancy-puerperal cycle. 69 The safety profile of these vaccines suggests that vaccines against SARS-CoV-2 infection employing inactivated viruses can be administered to pregnant and lactating women. 70 contains 600 SU of inactivated SARS-CoV-2 virus antigen in each dose. 4 The recommended vaccination schedule is based on two doses administered two to four weeks apart. 3, 72 This approach was reported to be 50.7% effective in preventing the spread of SARS-CoV-2 and from 83.7% to 100% effective in reducing moderate and severe disease, respectively. 4, 73 There was a low rate of reported adverse effects, mainly pain at the administration site (77.1%). All serious adverse reactions were considered unrelated to vaccination. 73 rate of local and systemic adverse reactions, without difference between study groups. 75 The first interim analysis of the phase 3 trial reported effectiveness of 80.6% against PCRconfirmed symptomatic COVID-19. 76, 77 There are two mRNA vaccines that are currently being widely marketed. The vaccine produced by Pfizer / BioNTech (Comirnaty ® , BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA), uses a vaccine schedule of two doses administered three weeks apart. 78 Each dose contains 30 μg of SARS-CoV-2 mRNA. The occurrence of mild adverse effects is higher in the vaccinated than in the placebo group (27% and 12%, respectively), mainly local pain, fatigue and headache, but severe adverse effects are rare and not different between groups. 5 This vaccine has a high effectiveness rate of 95%. 5 However, a low temperature is required for its storage and transportation, as it must be stored frozen at -60ºC to -90ºC. 79 The vaccine produced by Moderna (Moderna COVID-19 Vaccine ® , ModernaTX, Inc, Cambridge, Massachusetts, USA) also uses technology based on the application of SARS-CoV-2 mRNA. As with previously described vaccines, preclinical rodent data were not conducted early enough to support the inclusion of pregnant women in the subsequent large-scale clinical trial. Hence, pregnant women were deliberately excluded from COVID-19 vaccination trials. These rodent data showed that the vaccine mRNA-1273, when administered at a dose of 100 μg prior to mating or during pregnancy, was not associated with adverse events. 16 The full vaccination course involves two doses given four weeks apart. Each dose contains 100 μg of COVID-19 mRNA. The occurrence of mild adverse effects is also high compared to the BioNtech vaccine, mainly limited local reactions (84.2% versus 19.8% for Moderna and placebo groups) and grade 1 and 2 systemic (headache, fatigue, myalgia and arthralgia) adverse events (79.4% versus 36.5% after the second dose), but severe adverse effects are rare. 10 The reported effectiveness rate is high, reaching 94.1%. 10 This vaccine must be stored frozen at -25ºC to -15ºC. 79 Among the vaccines that use viral vectors technology, the Oxford/AstraZeneca vaccine uses an adenovirus (AD) ChAdOx1 (acronym for Chimpanzee Adenovirus Oxford 1) from chimpanzee as an antigen vector for the SARS-CoV-2 (Covishield ® , Oxford University, Oxford, UK; AstraZeneca, Södertälje, Sweden). Its effectiveness varies from 55.1% to 81.3% for second dose administration intervals less than 6 weeks or more than 12 weeks, respectively. Mild adverse effects such as local pain, headache, muscle pain, fever, and malaise are common, but similarly to the placebo group, only 0.9% of the vaccinated had serious adverse effects. 9 Recently, reports of the occurrence of rare central nervous system thrombosis and thrombocytopenia associated with positive antibodies to platelet factor 4, mainly in women under 30 years of age after ChAdOx1 vaccination, led some European countries to temporarily suspend its use or to recommend an alternative vaccine. [80] [81] [82] The vaccine produced by the Gamaleya Research Institute (Sputnik V ® , Gamaleya The vaccine produced by Janssen Pharmaceutical (Adenovirus 26) has just completed phase 3 of evaluation. One of its advantages is that the vaccination schedule involves only one dose, with effectiveness around 66% against moderate to severe-critical COVID-19 and varying from 76.7%% to 85.4% against severe-critical disease after 14 and 28 days of administration, respectively. 83 The storage temperature can vary between 2ºC and 8ºC, using common refrigeration. 11 The most common adverse effects were local reaction (48.6%), headache (38.9%), fatigue (38.2%), myalgia (33.2%) and nausea (14.2%). Serious adverse events occurred in 0.4% of vaccine recipients, similar to the placebo group. 83 Similarly to what happened with the adenovirus ChAdOx1 vaccine, reports of cerebral venous sinus thrombosis soon after administration led to temporary interruption of Ad26.COV.2.S vaccination in the United States, suggesting that the rare occurrence of vaccine-induced immune thrombotic thrombocytopenia could have a relation to adenoviral vector vaccines, although there are structural differences between these products. 84, 85 Vaccinating pregnant and lactating women

The promising results with vaccines against COVID-19 indicate that this will be the main strategy for overcoming the pandemic. 2, 86 However, there is still debate regarding its use in pregnant women, puerperal women, or lactating mothers, 87 a population at high risk of developing serious disease. 45 Animal data is also limited, but mRNA-1273 vaccine administration to rodent prior to mating or during pregnancy was not associated to adverse outcomes. 16 have provided vaccination guidance for lactating women taking into account regional differences regarding indication priorities and distribution issues. [87] [88] [89] [90] [91] [92] [93] 95, 96 In general, there is no contraindication for vaccination of this population and interruption of breastfeeding is not indicated for women receiving the vaccine. [87] [88] [89] [90] [91] [92] [93] 95, 96 These guidelines for vaccinating pregnant women and lactating mothers must be considered with precautionary measures while considering the ethical implications of denying access to resources that can save lives, such as the COVID-19 vaccine. 97 44, 102 At this moment, it seems reasonable to prioritize pregnant and lactating women vaccination using mRNA vaccines, followed by inactivated viruses vaccines, according to local availability. Additional information from clinical trials on vaccinated pregnant women will be critical for updating these guidelines.

In LMIC, the intrinsic economic, educational and social deprivation exacerbate the intrinsic difficulties in organizing adequate storage and distribution of vaccines and supplies, and 7) the failure to prioritize pregnant women as a group at higher risk for the most serious forms of COVID-19 in these settings. All these factors can be observed in varying degrees of intensity in LMIC and deserve special attention.

Although WHO classifies maternal antenatal, delivery and postnatal care health services as essential to continue during the COVID-19 pandemics, access to care seems to be more profoundly impacted in LMIC. In Nigeria, a country that accounts for 25% of global maternal mortality, 43.5% of pregnant women reported at least one challenge with accessing health care facilities, with close to a third that could not access these essential services at all due to COVID-19 lockdown or transport restrictions. 103 In Ethiopia, maternal health service access was not achieved by 35.2% of the pregnant women, mainly for the illiterate, the economic-dependent women, the mothers who had to travel more than 30 minutes to reach the health facility and those who did not practice COVID-19 prevention measures. 104 In a district in India, there was an overall decrease of 2.3% in the number of institutional deliveries, 22.9% in antenatal care and 20% in immunization services. 105 Distinct requirements for storage, transportation and administration schemes among different vaccines may also be a challenge for low-resource settings. While a one-dose regime (Janssen vaccine) could simplify the process, two-dose schemes with different time intervals between doses and the nRNA vaccines requirement for a -70 o C cold chain storage and transportation pose additional difficulties to many non-industrialized tropical climate countries. 106 In addition, vaccination hesitancy has been amplified globally by circulating rumors regarding an association of COVID-19 vaccination with subfertility, pregnancy and breastfeeding concerns, what might have a deeper impact in settings less prepared to promote concerted, multidisciplinary and multistakeholder public health interventions. 107 These reinforce the necessity of policies in LMIC to empower pregnant women, to create awareness on COVID-19 preventive measures and to facilitate access not only to maternal health care utilization, but also to vaccination sites. 106 Recently, artificial intelligence and machine learning are being explored as tools to diminish health inequalities and to decrease the burden on health systems in LMIC. Deep learning systems could also be utilized for studying viral components which could be utilized as antigens, accelerating traditional vaccine development and availability. 108 Data from a recent meta-analysis on the global changes in antenatal and maternity care provision during the COVID-19 pandemic highlighted the clear changes in healthcare usage and provision and in perinatal outcomes. 109 There was a marked reduction in antenatal care contacts, antenatal screening for infection and fetal anomaly, companionship in labor and postpartum length of hospital stay in most settings, and an obviously disproportionate increase in remote or virtual care provision between high-and LMIC. While in high income countries antenatal care has incorporated a hybrid model to keep the previous number of contacts, in LMIC there was a dismal reduction in antenatal care attendance. All these changes may pose additional risks to pregnant people and their offspring, and might be plausibly linked to the significant increase in maternal-fetal morbidity and mortality, COVID-19 related or not, in low resource countries as a result of a fall in pregnancy care attendance during this period. 109 Comparing the rates of COVID-19 related maternal death observed in LMIC with those observed in high-income settings, it is clear that they are objectively higher in the former countries, 110 such as Brazil, 47 México 111, 112 and some Asian countries. 113 As most of these data are derived from case series and reports, reliable maternal death rates are difficult to report, but a mortality rate of 12.7% has been already reported for the Brazilian obstetric population, compared to 0.8% from the WAPM study, which was mainly composed of European countries. 47, 110 In Mexico, 31% of maternal mortality was due to respiratory causes in 2020, compared to 5% from 2011 to 2019. COVID-19 was the leading cause (202/934 deaths, 21.6%). 112 The Brazilian Obstetric Observatory on COVID-19 (Brazilian`s Ministry of Health) weekly updates the number of deaths of pregnant and postpartum women due to COVID-19. While in 2020 there were 456 COVID-19-reported maternal deaths (average of 10 deaths/weekly), from January to the 18 th of August 2021 there were 1336 deaths (average of 42 maternal deaths/week). 32% of these women did not have access to intensive care facilities and were not intubated, denoting real difficulties in accessing advanced life support resources in this country. 114 The high rates of maternal mortality in these countries need to be faced without subterfuge, with a view to adopting measures, such as vaccine prioritization, that can compensate the lack of infrastructure and proper care for these women. Fortunately, Brazilian and Mexican governments recently launched a universal vaccination program for pregnant women. 101, 112 In Israel, for instance, a retrospective cohort of pregnant women vaccinated with BNT162b2 mRNA compared with no vaccination reported an adjusted hazard ratio of 0.22 (95% CI 0.11-0.43). 115 It is imperative to replicate this study findings with prospective design studies in LMIC, where, due to all the previously discussed restraints, the benefits could be majored.

In summary, the lack of data on efficacy and evaluation of immune response of vaccines against SARS-CoV-2 does not justify a passive attitude towards the request of pregnant, puerperal, and lactating women to be vaccinated. Especially in LMIC, where there is widespread transmission of SARS-CoV-2 and lack of vaccine supply, it is important to recognize that women in the pregnancy-puerperal cycle are at increased risk of severe COVID-19 and their offspring are at increased risk of the deleterious impact of preterm birth, making a strong case for primary prevention. Therefore, vaccination should be offered to all women in the pregnancy-puerperal cycle. For pregnant, puerperal, and lactating healthcare providers or those with risk comorbidities, a consensus will likely be reached that this group should be a priority for vaccination. 15, 91, 92 Notably, regardless of vaccination, pregnant women must maintain antenatal care and emphatically be guided regarding measures to reduce SARS-CoV-2 transmission, such as vigorous hand hygiene, social distancing and mask wearing. 116 

World Health Organization. World Health Organization (WHO) Coronavirus Disease (COVID-19) Dashboard

Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

COVID-19: Coronavirus Vaccine Development Updates

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

The Advisory Committee on Immunization Practices' Interim Recommendation for Allocation of COVID-19 Vaccine -United States

Pregnancy, Viral Infection, and COVID-19

The need for inclusion of pregnant women in COVID-19 vaccine trials

Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients

Moderna COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee FDA briefing document

Involving Pregnant Individuals in Clinical Research on COVID-19 Vaccines

COVID-19 vaccine response in pregnant and lactating women: a cohort study

Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

COVID-19 Vaccination in Pregnant and Lactating Women

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science (80-)

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

One year of SARS-CoV-2: How much has the virus changed?

An integrated approach to determine the abundance, mutation rate and phylogeny of the SARS-CoV-2 genome

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. Res Sq

Sixteen novel lineages of SARS-CoV-2 in South Africa

SARS-CoV-2 genomic surveillance in Rondônia

The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation

Pregnancy and infection

COVID-19 and pregnancy: An opportunity to correct an historic gender bias

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis

Outcomes of Critically Ill Pregnant Women with COVID-19 in the United States

Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory distress syndrome due to COVID-19 in Brazil

Clinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients: A systematic review and meta-analysis

Laboratory characteristics of pregnant compared to non-pregnant women infected with SARS-CoV-2

Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know

Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State

Public Health Agency of Sweden's Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden

Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls

Maternal, fetal and neonatal outcomes of large series of SARS-CoV-2 positive pregnancies in peripartum period: A single-center prospective comparative study

Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review

Pregnancy and Breastfeeding During COVID-19 Pandemic: A Systematic Review of Published Pregnancy Cases

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

The Profile of the Obstetric Patients with SARS-CoV-2 Infection According to Country of Origin of the Publication: A Systematic Review of the Literature

The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting

Maternal and perinatal outcomes related to COVID-19 and pregnancy: overview of systematic reviews

The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from

Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP-SONPM registries

Maternal and Neonatal Morbidity and Mortality among Pregnant Women with and without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

The impact of COVID-19 on pregnancy outcomes: A systematic review and meta-analysis

Maternal and perinatal outcomes in high compared to low risk pregnancies complicated by severe acute respiratory syndrome coronavirus 2 infection (phase 2): the World Association of Perinatal Medicine working group on coronavirus disease 2019

Risk Factors Associated with Adverse Fetal Outcomes in Pregnancies Affected by Coronavirus Disease 2019 (COVID-19): A Secondary Analysis of the WAPM study on COVID-19

Chronic Histiocytic Intervillositis with Trophoblast Necrosis are Risk Factors Associated with Placental Infection from

COVID-19) and Intrauterine Maternal-Fetal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transm. Arch Pathol Lab Med

Trophoblast damage with acute and chronic intervillositis: disruption of the placental barrier by severe acute respiratory syndrome coronavirus 2

Transplacental transmission of SARS-CoV-2 infection

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

Vertical transmission of coronavirus disease 2019

Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates

Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates

Vertical Transmission of SARS-CoV-2: What is the Optimal Definition?

Synthesis and systematic review of reported neonatal SARS-CoV-2 infections

World Health Organization. Definition and Categorization of the Timing of Mother-to-Child Transmission of SARS-CoV-2

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

A systematic review of SARS-CoV-2 vaccine candidates

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. npj Vaccines

The historical aspects of vaccination in pregnancy

The Pregnancy and Influenza Multinational Epidemiologic (PRIME) study: a prospective cohort study of the impact of influenza during pregnancy among women in middle-income countries

The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review

The safety of influenza and pertussis vaccination in pregnancy in a cohort of australian mother-infant pairs

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Efficacy and Safety of a COVID-19

Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN Electron J. 2021

Autorização temporária de uso emergencial da vacina adsorvida Covid-19 (inativada)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Bharat Biotech Announces Phase 3 Results of COVAXIN ® : India ' s First COVID -19 Vaccine Demonstrates Interim Clinical Efficacy of 81 %

What do we know about India's Covaxin vaccine?

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -United States

COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination -Response from the Manufacturer

World Health Organization. Covid-19 vaccines

Equity in coronavirus disease 2019 vaccine development and deployment

American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19: Practice advisory

Society for Maternal-Fetal Medicine. SMFM: provider considerations for engaging in COVID-19 vaccine counselling with pregnant and lactating patients

COVID-19 vaccines, pregnancy and breastfeeding

Nota Técnica do Ministério da Saúde Sobre Administração de vacinas COVID-19 em Gestantes, Puérperas e Lactantes

International Federation Gynecology and Obstetrics. COVID-19 Vaccination for Pregnant and Breastfeeding Women. FIGO Statement

Ministry of Health. Vaccinating Women who are Planning a Pregnancy, Pregnant or Breastfeeding with the COVID-19 Vaccine -Clarification

Breast milk and covid-19: From conventional data to "omics" technologies to investigate changes occurring in sars-cov-2 positive mothers

Why were breastfeeding women in the UK denied the covid-19 vaccine?

Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies

Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making

Preliminary Findings of mRNA Covid-19

Vaccine Safety in Pregnant Persons

JCVI statement on use of the AstraZeneca COVID-19 vaccine

COVID-19 vaccines, pregnancy and breastfeeding

The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations

Challenges in access and satisfaction with reproductive, maternal, newborn and child health services in Nigeria during the COVID-19 pandemic: A cross-sectional survey. Hodges MH

Maternal health care services utilization amidstCOVID-19 pandemic in West Shoa zone

Impact of COVID-19 pandemic on maternal and child health services in Uttar Pradesh

Considerations for establishing successful coronavirus disease vaccination programs in Africa

Vaccination hesitancy among women of reproductive age in resource-challenged settings: A cause for public health concern

Exploring the Potential of Artificial Intelligence and Machine Learning to Combat COVID-19 and Existing Opportunities for LMIC: A Scoping Review

Global changes in maternity care provision during the COVID-19 pandemic: A systematic review and meta-analysis

Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection

Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx)

A forecast of maternal deaths with and without vaccination of pregnant women against COVID-19 in Mexico

Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women -a systematic review and meta-analysis

Ministério da Saúde do Brasil. Brazilian Obstetric Observatory on COVID-19 (Observatório Obstétrico Brasileiro COVID-19)

Association between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women

Vaccination Considerations for People who are Pregnant or Breastfeeding